John Kapeghian, Ph.D.
Senior Vice President of Global Safety & Toxicology
Dr. John Kapeghian, PhD, DABT is Frontage’s Senior Vice President, Global Safety & Toxicology. John brings over 35 years of experience in global preclinical safety evaluation and development. After working in regulatory and experimental toxicology units at large pharma (Ciba now Novartis) and in contract research (Sierra Biomedical/Charles River), he established his own company, Preclinical Safety Associates, which provides toxicology strategy and regulatory services for over 90 companies worldwide since 2006.
As a subject matter expert and a recognized leader in the Safety and Toxicology space, John has served on the Toxicology Advisory Board of Genzyme Pharmaceuticals and has been a Section Editor at the International Journal of Toxicology for over 20 years. He has over 100 abstracts, presentations, and publications to his credit.
During his tenure in pharma, contract research, and consulting, John helped write preclinical dossiers supporting human safety for regulatory authorities in the US, UK, EU, Canada, India, and Asia. John’s passion for quality in toxicology data evaluation and interpretation led him to form a company in 2008 dedicated to training Study Directors, with additional workshops in clinical pathology and project management. John continues to train Study Directors via courses and workshops at national toxicology meetings, and through his consulting practice, book chapters, and numerous publications.
John received his Ph.D. in Pharmacology/ Toxicology from the University of Mississippi School of Pharmacy in Oxford MS and is current with his DABT certification.